Author: CSANZ Admin

In this edition:

–  Semaglutide in HFPEF according to obesity/weight loss
–  Catheter ablation for end-stage HF with AF
–  Adaptive vs. conventional CRT for HF
–  NYHA class and KCCQ in acute HF
–  Remote multiparameter monitoring for guiding HF management
–  Upgrade of right ventricular pacing to CRT in HF
–  Update of ESC HF guidelines
–  Mortality, outcomes, costs and medication use after first HF hospitalisation
–  MRA initiation during admission improves outcomes in acute HF

Download Heart Failure Research Review Issue 81 as a pdf here 

A new Research Review Educational series on cardiac adverse reactions associated with cancer immunotherapy.  This series summarises the impact, diagnosis, and management of cardiac immune-related adverse reactions in these patients, using current clinical consensus. The review also presents and discusses two cases of ICI-associated myocarditis with very different outcomes.

Independent commentary is provided by Dr James Pemberton, a cardiologist currently working at Dunedin and Invercargill Hospitals.

 Download Educational_Series_Cardiac_Adverse_Reactions_and_Immunotherapy (pdf)

In this issue:

• ANGPTL3 might be a suitable target for triglyceride and cholesterol lowering
• Complete vs culprit-only PCI in older patients with MI
• Catheter ablation reduces psychological distress in patients with AF
• Outcomes of thrombus aspiration during PCI for STEMI
• Benefits of lipid-lowering therapy for primary prevention in the elderly
• Outcomes after PCI in patients with ischaemic LV dysfunction
• Prognostic significance of ventricular ectopic beats during exercise
• Ten-year cardiovascular risk in patients with newly diagnosed type 2 diabetes
• Impact of smoking status on cardiovascular outcomes after PCI

Download Cardiology_Research_Review_Issue_158 (pdf)

Cardiology Watch 9 – The emerging role of fish oil in reducing cv events presented by A/Prof John Amerena

Cardiology Watch is a video series produced by Research Review.

Each video introduces an educational topic or study presented by Australian specialists and captures the local flavour of Cardiology practice. If you missed any previous episodes see links below:

• Cardiology Watch 8 – The role of GLP1 agonists in treatment and prevention of CV disease presented by A/Prof John Amerena
• Cardiology Watch 7 – Should Australia lower LDL-C targets to match the European guidelines? presented by A/Prof John Amerena
• Cardiology Watch 6 – Strategies to Reduce Residual Risk in Patients with ASCVD with a focus on the role of Inflammation and Lp(a) presented by A/Prof John Amerena
• Cardiology Watch 5 – Strategies to Reduce Residual Risk in Patients with ASCVD presented by A/Prof John Amerena
• Cardiology Watch 4 – Heart failure and AF: New Options for Better Outcomes   presented by A/Prof John Amerena
• Cardiology Watch 3 – SGLT2s in Heart Failure  presented by A/Prof John Amerena
• Cardiology Watch 2 – Lipid Management to Prevent ASCVD; Targeting New Lipid Components  presented by Prof Philip Aylward

In this edition:

–  Ferric carboxymaltose in HF with iron deficiency
–  Semaglutide in HFPEF and obesity
–  Clinical characteristics and HF outcomes: LVEF thresholds and inflection points
–  Obesity in HFPEF with or without diabetes
–  VAI and HF risk, late-life cardiac structure and function
–  Blinded withdrawal of long-term empagliflozin or placebo in HF
–  Cardiac and metabolic effects of dapagliflozin in HFPEF
–  Age, sex and outcomes in HFREF
–  5-year mortality in patients managed with magnetically levitated LVAD
–  MRA underutilisation in HFREF

Download  Heart_Failure_Research_Review_Issue_80 (pdf)